Presentation is loading. Please wait.

Presentation is loading. Please wait.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria 

Published byRobert Thornton Modified over 5 years ago

Similar presentations

Presentation on theme: "A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria "— Presentation transcript:

1 A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria  Sarbjit Saini, MD, Karin E. Rosen, MD, PhD, Hsin-Ju Hsieh, PhD, Dennis A. Wong, MD, Edward Conner, MD, Allen Kaplan, MD, Sheldon Spector, MD, Marcus Maurer, MD  Journal of Allergy and Clinical Immunology  Volume 128, Issue 3, Pages e1 (September 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Study design. OMA, Omalizumab.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Flow diagram based on Consolidated Standards of Reporting Trials (CONSORT) guidelines. OMA, Omalizumab. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Mean ± SD for changes from baseline to week 4 in UAS7. P values are based on comparison with the placebo group by using the Van Elteren test. OMA, Omalizumab. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Mean change from baseline in UAS7 by week during the treatment period. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Mean ± SD for changes from baseline to week 4 in weekly itch and weekly hive scores. P values are based on comparison with the placebo group by using the Van Elteren test. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria "

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial Saifudin.

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial Saifudin.
Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,
Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A
Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy  Thomas B. Casale, MD, Jonathan A. Bernstein,

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy  Thomas B. Casale, MD, Jonathan A. Bernstein,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Dennis K. Ledford, MD, Sally Wenzel, MD 

Dennis K. Ledford, MD, Sally Wenzel, MD 
Shyam Joshi, MD, David A. Khan, MD 

Shyam Joshi, MD, David A. Khan, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Children with allergic and nonallergic rhinitis have a similar risk of asthma  Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Children with allergic and nonallergic rhinitis have a similar risk of asthma  Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Similar presentations

Ads by Google